Evidence map›Paper›PMID 38438663›Full record

ArticleHuman cell2024

Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetes retinopathy.

Lihua Hou, Jianying Du, Yongxiao Dong, Min Wang, Libo Wang, Jifei Zhao

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Liraglutide Ameliorates Injury-Related Vascular Repair by Activating Autophagy Through Modulation of the PI3K-mTOR Signaling Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lihua HouDepartment of Ophthalmology, The First People's Hospital of Xianyang, No. 10, Biyuan Road, Qindu District, Xianyang City, 712000, Shanxi, China.
Jianying DuDepartment of Ophthalmology, The First People's Hospital of Xianyang, No. 10, Biyuan Road, Qindu District, Xianyang City, 712000, Shanxi, China.
Yongxiao DongDepartment of Ophthalmology, The First People's Hospital of Xianyang, No. 10, Biyuan Road, Qindu District, Xianyang City, 712000, Shanxi, China.
Min WangDepartment of Ophthalmology, The First People's Hospital of Xianyang, No. 10, Biyuan Road, Qindu District, Xianyang City, 712000, Shanxi, China.
Libo WangDepartment of Ophthalmology, Sanyuan Eye Hospital, Xianyang City, 713899, Shanxi, China.
Jifei ZhaoDepartment of Ophthalmology, The First People's Hospital of Xianyang, No. 10, Biyuan Road, Qindu District, Xianyang City, 712000, Shanxi, China. jfzhao0323@yeah.net.ORCID http://orcid.org/0000-0002-8967-5623
Xian Yang Central Hospital · CNShanxi Eye Hospital · CN

Funding

2020 municipal key R&D Projects of Xianyang City 2020k02-102
6 · The paper itself

Abstract

Diabetes mellitus (DM) is a chronic metabolic disorder affecting millions of people worldwide, characterized by dysregulated glucose homeostasis and hyperglycemia. Diabetic retinopathy (DR) is one of the serious multisystemic complications. Aging is an important risk factor for DR. Endothelial sirtuin 1 (SIRT1) plays an important role in regulating the pathophysiology of glucose metabolism, cellular senescence, and aging. Liraglutide, an analog of Glucagon-like peptide 1 (GLP-1), has been widely used in the treatment of DM. However, the effects of Liraglutide on DR are less reported. Here, we investigated whether treatment with Liraglutide has beneficial effects on high glucose (HG)-induced injury in human retinal microvascular endothelial cells (HRECs). First, we found that exposure to HG reduced the expression of glucagon-like peptide 1 receptor 1 (GLP-1R). Additionally, Liraglutide ameliorated HG-induced increase in the expression of vascular endothelial growth factor-A (VEGF-A) and interleukin 6 (IL-6). Importantly, Liraglutide ameliorated cellular senescence and increased telomerase activity in HG-challenged HRECs. Liraglutide also reduced the levels of p53 and p21. Mechanistically, Liraglutide restored the expression of SIRT1 against HG. In contrast, the knockdown of SIRT1 abolished the protective effects of Liraglutide in cellular senescence of HRECs. Our findings suggest that Liraglutide might possess a benefit on DR mediated by SIRT1.

Indexed as

Diabetes MellitusDiabetic RetinopathyCellular SenescenceEndothelial CellsGlucoseHumansLiraglutideSirtuin 1Vascular Endothelial Growth Factor AGlucoseLiraglutideSIRT1 protein, humanSirtuin 1Vascular Endothelial Growth Factor ADiabetic retinopathyGlucagon-like peptide 1 (GLP-1)High glucoseLiraglutideSenescence

Identifiers

PMID38438663
PMCPMC11016519
OpenAlexW4392383337

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.